Skip to content

Nuvation Bio NUVB Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Pfizer logo
PfizerPFE
Nuvalent, Inc. logo
Nuvalent, Inc.NUVL
Immunome logo
ImmunomeIMNM
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
Arcus Biosciences logo
Arcus BiosciencesRCUS

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's deferred tax assets and other non-current assets?
Nuvation Bio (NUVB) reported deferred tax assets and other non-current assets of $3.82M in Q1 2026.
How has Nuvation Bio's deferred tax assets and other non-current assets changed year-over-year?
Nuvation Bio's deferred tax assets and other non-current assets decreased by 42.2% year-over-year, from $6.62M to $3.82M.